Willis Towers Watson plc 8.3

Source: RNS
RNS Number : 8845C
J.P. Morgan Securities LLC
23 June 2021
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

J.P. Morgan Securities LLC

Company dealt in

Willis Towers Watson plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.000304635 ordinary shares

Date of dealing

22 June 2021

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

1,912,341                1.48

1,696,530             1.32

(2) Derivatives (other than options)

1,691,904                1.31

1,738,715                1.35

(3) Options and agreements to purchase/sell

 

7,800             0.01

600             0.00

Total

3,612,045             2.80

3,435,845             2.67

             

 

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (USD)

 

(Note 5)

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

Purchases

 

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

200

 13

 400

 100

 682

 167,039

 100

 4

 4

 9

 6

 

 1

 1

 1

 1

 10

 1

 1

 3

 4

 2

 2

 1

 8

 2

 1

 1

 2

 2

 43

 1

 3

 400

 1

 1

 5

 18

 1

 7

 124

 5,824

 527

 1

 6

 4

 6

 6

231.2174     USD

231.1250     USD

230.8162     USD

230.5100     USD

230.4176     USD

230.4100     USD

230.3000     USD

230.1800     USD

230.1750     USD

229.7550     USD

229.3400     USD

                       

231.8600     USD

231.7900     USD

231.5800     USD

231.5200     USD

231.4580     USD

231.4500     USD

231.3800     USD

231.2000     USD

231.1900     USD

231.1750     USD

231.1250     USD

231.0700     USD

231.0200     USD

231.0000     USD

230.9900     USD

230.9200     USD

230.9150     USD

230.8900     USD

230.8850     USD

230.8400     USD

230.8200     USD

230.8162     USD

230.7900     USD

230.7500     USD

230.5380     USD

230.5300     USD

230.5100     USD

230.4743     USD

230.4415     USD

230.4100     USD

230.4072     USD

230.3000     USD

230.2900     USD

230.1800     USD

229.3600     USD

229.3400     USD

 

 

 

 

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(USD) (Note 5)

Equity Swap

Decrease Short

 

Increase Short

6

 

 400

229.3394     USD

                       

230.8162     USD

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price (USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5) (USD)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

                         

 

Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. 

If none, this should be stated.

 

     None

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            Yes

 

Date of disclosure

23 June 2021

Contact name

Alwyn Basch

Telephone number

0207 742 7407

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

 

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL FORM 8

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

 

 

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

OPEN POSITIONS (Note 1)

 

 

 

Product name,

e.g. call option

Written, or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2) (USD)

Type, e.g. American, European etc.

Expiry date

Call Option

Put Option

Put Option

Purchased

Purchased

Written

3,900
3,900
600

240.0000

220.0000

250.0000

American

American

American

 

16/07/2021

16/07/2021

16/07/2021

 

 

Notes

 

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details 

             of any existing agreements to purchase or to sell must also be given on this form.

 

2.          For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEXXLFLFQLLBBD